Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

por Digumarthy, Subba R., Mendoza, Dexter P., Zhang, Eric W., Lennerz, Jochen K., Heist, Rebecca S.
Publicado 2019

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

por Schram, Alison M., Gandhi, Leena, Mita, Monica M., Damstrup, Lars, Campana, Frank, Hidalgo, Manuel, Grande, Enrique, Hyman, David M., Heist, Rebecca S.
Publicado 2018

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation

por Wu, Markus Y., Zhang, Eric W., Strickland, Matthew R., Mendoza, Dexter P., Lipkin, Lev, Lennerz, Jochen K., Gainor, Justin F., Heist, Rebecca S., Digumarthy, Subba R.
Publicado 2021

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer

por Hellmann, Matthew D., Gettinger, Scott, Chow, Laura Q. M., Gordon, Michael, Awad, Mark M., Cha, Edward, Gong, Xiaohua, Zhou, Gongfu, Walker, Chris, Leopold, Lance, Heist, Rebecca S.
Publicado 2020

Impact on Disease Development, Genomic Location and Biological Function of Copy Number Alterations in Non-Small Cell Lung Cancer

por Huang, Yen-Tsung, Lin, Xihong, Chirieac, Lucian R., McGovern, Ray, Wain, John C., Heist, Rebecca S., Skaug, Vidar, Zienolddiny, Shanbeh, Haugen, Aage, Su, Li, Christiani, David C.
Publicado 2011

Phase II Study of Cabozantinib in Patients With Bone Metastasis

por Choy, Edwin, Cote, Gregory M, Michaelson, M Dror, Wirth, Lori, Gainor, Justin F, Muzikansky, Alona, Sequist, Lecia V, Sullivan, Ryan J, Fidias, Panagiotis M, Shaw, Alice, Heist, Rebecca S
Publicado 2022

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

por Schneider, Jaime L., Muzikansky, Alona, Lin, Jessica J., Krueger, Elizabeth A., Lennes, Inga T., Jacobson, Joseph O., Cheng, Michael, Heist, Rebecca S., Piotrowska, Zofia, Gainor, Justin F., Shaw, Alice T., Dagogo-Jack, Ibiay
Publicado 2022

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

por Cooper, Alissa J., Muzikansky, Alona, Lennerz, Jochen, Narinesingh, Farhaana, Mino-Kenudson, Mari, Hung, Yin P., Piotrowska, Zofia, Dagogo-Jack, Ibiayi, Sequist, Lecia V., Gainor, Justin F., Lin, Jessica J., Heist, Rebecca S.
Publicado 2022

Intracranial Efficacy of Adagrasib in Patients From the KRYSTAL-1 Trial With KRAS(G12C)-Mutated Non–Small-Cell Lung Cancer Who Have Untreated CNS Metastases

por Negrao, Marcelo V., Spira, Alexander I., Heist, Rebecca S., Jänne, Pasi A., Pacheco, Jose M., Weiss, Jared, Gadgeel, Shirish M., Velastegui, Karen, Yang, Wenjing, Der-Torossian, Hirak, Christensen, James G., Sabari, Joshua K.
Publicado 2023

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

por Dagogo-Jack, Ibiayi, Kiedrowski, Lesli A., Heist, Rebecca S., Lin, Jessica J., Meador, Catherine B., Krueger, Elizabeth A., Do, Andrew, Peterson, Jennifer, Sequist, Lecia V., Gainor, Justin F., Lennerz, Jochen K., Digumarthy, Subba R.
Publicado 2023

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

por Kim, Dong-Wan, Gadgeel, Shirish, Gettinger, Scott N., Riely, Gregory J., Oxnard, Geoffrey R., Mekhail, Tarek, Schmid, Peter, Dowlati, Afshin, Heist, Rebecca S., Wozniak, Antoinette J., Singh, Jatinder, Cha, Edward, Spahn, Jessica, Ou, Sai-Hong Ignatius
Publicado 2022

Inflammation-related Genetic Variations and Survival for Advanced Non-Small Cell Lung Cancer Receiving First-line Chemotherapy

por Pu, Xia, Hildebrandt, Michelle A., Lu, Charles, Roth, Jack A., Stewart, David J., Zhao, Yang, Heist, Rebecca S., Ye, Yuanqing, Chang, David W., Su, Li, Minna, John D., Lippman, Scott M., Spitz, Margaret R., Christiani, David C., Wu, Xifeng
Publicado 2014

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

por Bauer, Todd, Cho, Byong Chul, Heist, Rebecca, Bazhenova, Lyudmila, Werner, Theresa, Goel, Sanjay, Kim, Dong-Wan, Adkins, Douglas, Carvajal, Richard D., Alva, Ajjai, Eaton, Keith, Wang, Judy, Liu, Yong, Yan, Xiaohong, Christensen, Jamie, Neuteboom, Saskia, Chao, Richard, Pant, Shubham
Publicado 2022

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lun...

por Shimizu, Toshio, Sands, Jacob, Yoh, Kiyotaka, Spira, Alexander, Garon, Edward B., Kitazono, Satoru, Johnson, Melissa L., Meric-Bernstam, Funda, Tolcher, Anthony W., Yamamoto, Noboru, Greenberg, Jon, Kawasaki, Yui, Zebger-Gong, Hong, Kobayashi, Fumiaki, Phillips, Penny, Lisberg, Aaron E., Heist, Rebecca S.
Publicado 2023

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

por Camidge, D. Ross, Morgensztern, Daniel, Heist, Rebecca S., Barve, Minal, Vokes, Everett, Goldman, Jonathan W., Hong, David S., Bauer, Todd M., Strickler, John H., Angevin, Eric, Motwani, Monica, Parikh, Apurvasena, Sun, Zhaowen, Bach, Bruce Allen, Wu, Jun, Komarnitsky, Philip B., Kelly, Karen
Publicado 2021

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

por Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Spira, Alex, Angevin, Eric, Su, Wu-Chou, Hong, David S., Strickler, John H., Motwani, Monica, Dunbar, Martin, Parikh, Apurvasena, Noon, Elysa, Blot, Vincent, Wu, Jun, Kelly, Karen
Publicado 2023

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

por Camidge, D. Ross, Barlesi, Fabrice, Goldman, Jonathan W., Morgensztern, Daniel, Heist, Rebecca, Vokes, Everett, Angevin, Eric, Hong, David S., Rybkin, Igor I., Barve, Minal, Bauer, Todd M., Delmonte, Angelo, Dunbar, Martin, Motwani, Monica, Parikh, Apurvasena, Noon, Elysa, Wu, Jun, Blot, Vincent, Kelly, Karen
Publicado 2021

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

por Piper-Vallillo, A.J., Rotow, Julia K., Aredo, Jacqueline V., Shaverdashvili, Khvaramze, Luo, Jia, Carlisle, Jennifer W., Husain, Hatim, Muzikansky, Alona, Heist, Rebecca S., Rangachari, Deepa, Ramalingam, Suresh S., Wakelee, Heather A., Yu, Helena A., Sequist, Lecia V., Bauml, Joshua M., Neal, Joel W., Piotrowska, Zofia
Publicado 2022

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRAS(G12C)-Mutant Non–Small Cell Lung Cancer

por Sabari, Joshua K., Velcheti, Vamsidhar, Shimizu, Kazuhide, Strickland, Matthew R., Heist, Rebecca S., Singh, Mohini, Nayyar, Naema, Giobbie-Hurder, Anita, Digumarthy, Subba R., Gainor, Justin F., Rajan, Anant P., Nieblas-Bedolla, Edwin, Burns, Aaron C., Hallin, Jill, Olson, Peter, Christensen, James G., Kurz, Sylvia C., Brastianos, Priscilla K., Wakimoto, Hiroaki
Publicado 2022

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

por Drilon, Alexander, Clark, Jeffrey W., Weiss, Jared, Ou, Sai-Hong Ignatius, Camidge, D. Ross, Solomon, Benjamin J., Otterson, Gregory A., Villaruz, Liza C., Riely, Gregory J., Heist, Rebecca S., Awad, Mark M., Shapiro, Geoffrey I., Satouchi, Miyako, Hida, Toyoaki, Hayashi, Hidetoshi, Murphy, Danielle A., Wang, Sherry C., Li, Sherry, Usari, Tiziana, Wilner, Keith D., Paik, Paul K.
Publicado 2020